论文部分内容阅读
目的：研究探讨将奥美拉唑与硫糖铝联合应用于急性出血性胃炎的具体效果。方法选择2014年9月-2015年11月于我院收治的急性出血性胃炎110例患者，分为对照组（奥美拉唑治疗）和观察组（奥美拉唑联合硫糖铝治疗）各55例，对比两组疗效。结果观察组的出血量及止血时间分别为（186.78±65.79）mL、（29.86±2.57）h，均较对照组有明显缩短（t=11.67，12.58；P＜0.05）；观察组的不良反应率为1.82%，显著低于对照组（X2=7.65，P＜0.05）。结论急性出血性胃炎患者予以奥美拉唑联合硫糖铝治疗能明显改善疗效，降低不良反应风险，具备推广价值。“,”Objective: To investigate the omeprazole and sucr alfate used in acute hemorrhagic gastritis concrete results.Methods: According to a completely random number table method, Septem ber 2014 - November 2015 in our hospital 110 cases of acute he morrhagic gastritis were divided into control group (omeprazole) and observation group (omeprazole sucralfate therapy) all 55 cas es, compared to the two groups.Results: The amount of bleeding and bleeding time of the observation group were (186.78 ± 65.7 9) mL, (29.86 ± 2.57) h, compared with the control group was significantly shorter (t = 11.67,12.58; P <0.05); advers e reactions observed group It was 1.82%, significantly lower than the control group (X2 = 7.65, P <0.05).Conclusion: Acute he morrhagic gastritis omeprazole and sucralfate therapy can be signifi cantly improved efficacy and reduce the risk of adverse reactions, have promotional value.